Category: WFN1 Contributors

12314110 / 1401 POSTS
Notice it says sell first and negotiate second. It does not say negotiate first and then try to sell. It’s important that you don’t forget which one comes first! Let me share a paragraph from my new book, A Mind for Sales: One of the great mi ...
By John Vandermosten, CFANASDAQ:PHIOREAD THE FULL PHIO RESEARCH REPORT Full Year 2019 Financial & Operational Update Phio Pharmaceuticals Corp. (NASDAQ:PHIO) reported full year 2019 results and filed its Form 10-K on March 26, 2020. The prior yea ...
By John Vandermosten, CFATSX:PMN.TO | OTC:ARFXFREAD THE FULL PMN.TO RESEARCH REPORT Full Year 2019 Operational and Financial Results 2019 provided a wild ride in the β-amyloid (βA) space. In March 2019, Biogen (NASDAQ:BIIB) announced that its Phase ...
By John Vandermosten, CFATSX:HBP.TO | OTC:HBPCF READ THE FULL HBP.TO RESEARCH REPORT Second Quarter 2019 Operational and Financial Results Helix BioPharma Corp. (TSX:HBP.TO) (OTC:HBPCF) reported second quarter 2020 results and submitted its SEDAR fi ...
By John Vandermosten, CFANASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT 2019 Operational and Financial Results On March 13, 2020 Lipocine (NASDAQ:LPCN) filed its fiscal year 2019 10-K and posted its earnings release for the twelve-month period ending ...
By John Vandermosten, CFANASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT Fourth Quarter and Full Year 2019 Review Achieve Life Sciences, Inc. (NASDAQ:ACHV) reported fourth quarter and full year results in a press release and conference call held on Ma ...
I am excited to share a special blog with you on this Monday morning. At my publisher’s request, I wrote an article for their Leadership Essentials blog. Over the last 18 months, it’s been an honor and a privilege to get to work wit ...
By Ann Heffron, CFA, CPAOTC:CPKF READ THE FULL CPKF RESEARCH REPORT Chesapeake Financial’s (OTC:CPKF) fourth quarter net earnings rose $61,000, or 3%, year over year to $1.9 million, while 2019’s fourth quarter diluted EPS increased by $0.02, or 3%, ...
By David Bautz, PhDNASDAQ:TNXP READ THE FULL TNXP RESEARCH REPORT Business Update Interim Analysis of Phase 3 RELIEF Trial in 3Q20 In December 2019, Tonix Pharmaceutical Holding Corp. (NASDAQ:TNXP) announced the first participant enrolled into the Ph ...
By David Bautz, PhDNASDAQ:DFFN READ THE FULL DFFN RESEARCH REPORT Business Update Evaluating TSC as Treatment for ARDS On April 1, 2020, Diffusion Pharmaceuticals, Inc. (NASDAQ:DFFN) announced that the company will be evaluating its lead development ...
12314110 / 1401 POSTS